Cook MyoSite

Executive Summary

Cook MyoSite is a clinical-stage biotechnology company pioneering autologous muscle-derived cell therapies for muscle-related disorders. Founded in 2002 and headquartered in Pittsburgh, the company leverages its proprietary muscle cell technology to develop treatments for conditions such as urinary and fecal incontinence. Its lead investigational product, iltamiocel (formerly known as MD-001), is an autologous muscle-derived cell therapy designed to restore muscle function. The company also supplies primary human skeletal muscle cells and research services to the scientific community. Cook MyoSite has demonstrated proof-of-concept in early clinical trials and is advancing toward pivotal studies. With a focus on addressing significant unmet medical needs in urology and gastroenterology, the company represents a niche player in the cell therapy space with potential for regulatory and commercial milestones.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 trial for iltamiocel in stress urinary incontinence70% success
• Q2 2027Presentation of Phase 2 data at major medical conference80% success
• Q1 2027Strategic partnership for manufacturing or commercialization50% success